SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION ARTICLE H impact

MedPal AI gets FDA approval for Mounjaro heart protection

MedPal AI PLC said the FDA approved tirzepatide (Mounjaro) to cut the risk of heart attack and stroke in type 2 diabetes, expanding its GLP-1 market reach.

MPAL

MedPal AI plc ("MedPal", the "Company" or the "Group") said on 01 September 2026 that the FDA approved tirzepatide to cut the risk of heart attack and stroke in type 2 diabetes, expanding the GLP-1 market. The source text also referred to El…

Related stories